T 1601/22 of 10.10.2024
- European Case Law Identifier
- ECLI:EP:BA:2024:T160122.20241010
- Date of decision
- 10 October 2024
- Case number
- T 1601/22
- Online on
- 23 December 2025
- Petition for review of
- -
- Application number
- 18179669.9
- IPC class
- A61K 38/12A61P 3/10A61K 38/20
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- IL-2 dosage regimen for treating systemic lupus erythematosus
- Applicant name
- ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS
Sorbonne Université
INSERM (Institut National de la Santé
et de la Recherche Médicale) - Opponent name
- STRAWMAN LIMITED
- Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention Art 54(2)European Patent Convention Art 56European Patent Convention Art 76(1)European Patent Convention Art 83European Patent Convention Art 87Rules of procedure of the Boards of Appeal Art 12(4)
- Keywords
- Auxiliary request 4 - allowable
- Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division with the order to maintain the patent as amended in the following version:
Claims:
No. 1 to 13 according to auxiliary request 4 filed with the patent proprietors' statement of grounds of appeal.
Description:
Paragraphs [0001] to [0007], [0009] to [0038], [0043], [0045] to [0096], and [0098] to [0178] of the patent specification,
paragraphs [0008], [0039], [0044] and [0097] as filed during the oral proceedings before the opposition division on 28 March 2022.
Drawings:
Figures 1 to 9 of the patent specification.